DexCom Inc.

107.87+0.1600+0.15%Vol 1.35M1Y Perf -1.11%
Feb 2nd, 2023 13:16 DELAYED
BID107.86 ASK107.89
Open109.17 Previous Close107.71
Pre-Market108.46 After-Market-
 0.75 0.70%  - -
Target Price
125.00 
Analyst Rating
Strong Buy 1.33
Potential %
15.94 
Finscreener Ranking
★★★     48.41
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     39.51
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     64.78
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
60.37 
Earnings Rating
Sell
Market Cap41.67B 
Earnings Date
9th Feb 2023
Alpha0.03 Standard Deviation0.16
Beta1.02 

Today's Price Range

107.37110.50

52W Range

66.89134.77

5 Year PE Ratio Range

-86.50418.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
0.99%
1 Month
-4.88%
3 Months
-7.11%
6 Months
21.98%
1 Year
-1.11%
3 Years
78.96%
5 Years
652.16%
10 Years
2 677.82%

TickerPriceChg.Chg.%
DXCM107.870.16000.15
AAPL150.074.64003.19
GOOG107.446.01475.93
MSFT261.879.11503.61
XOM111.52-3.2181-2.80
WFC47.350.32300.69
JNJ163.86-1.0650-0.65
FB196.640.99000.51
GE83.731.41001.71
JPM139.17-0.4200-0.30
 
ProfitabilityValueIndustryS&P 500US Markets
65.00
10.10
15.50
-0.50
11.91
RevenueValueIndustryS&P 500US Markets
2.09B
5.42
26.79
32.99
Earnings HistoryEstimateReportedSurprise %
Q03 20220.240.2816.67
Q02 20220.170.170.00
Q01 20220.130.08-38.46
Q04 20210.220.17-22.73
Q03 20210.160.2237.50
Q02 20210.110.1972.73
Q01 20210.080.080.00
Q04 20200.910.910.00
Earnings Per EndEstimateRevision %Trend
12/2022 QR0.26-13.33Negative
12/2022 FY0.790.00-
3/2023 QR0.16-5.88Negative
12/2023 FY1.08-1.82Negative
Next Report Date9th Feb 2023
Estimated EPS Next Report0.26
Estimates Count11
EPS Growth Next 5 Years %32.90
Volume Overview
Volume1.35M
Shares Outstanding386.26K
Shares Float349.30M
Trades Count25.86K
Dollar Volume146.89M
Avg. Volume2.34M
Avg. Weekly Volume2.04M
Avg. Monthly Volume2.50M
Avg. Quarterly Volume2.48M

DexCom Inc. (NASDAQ: DXCM) stock closed at 107.71 per share at the end of the most recent trading day (a 0.58% change compared to the prior day closing price) with a volume of 2.85M shares and market capitalization of 41.67B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 7000 people. DexCom Inc. CEO is Kevin R. Sayer.

The one-year performance of DexCom Inc. stock is -1.11%, while year-to-date (YTD) performance is -4.88%. DXCM stock has a five-year performance of 652.16%. Its 52-week range is between 66.8925 and 134.765, which gives DXCM stock a 52-week price range ratio of 60.37%

DexCom Inc. currently has a PE ratio of 263.20, a price-to-book (PB) ratio of 24.52, a price-to-sale (PS) ratio of 20.30, a price to cashflow ratio of 72.20, a PEG ratio of 2.32, a ROA of 4.07%, a ROC of 6.08% and a ROE of 10.01%. The company’s profit margin is 11.91%, its EBITDA margin is 15.50%, and its revenue ttm is $2.09 Billion , which makes it $5.42 revenue per share.

Of the last four earnings reports from DexCom Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.26 for the next earnings report. DexCom Inc.’s next earnings report date is 09th Feb 2023.

The consensus rating of Wall Street analysts for DexCom Inc. is Strong Buy (1.33), with a target price of $125, which is +15.94% compared to the current price. The earnings rating for DexCom Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

DexCom Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

DexCom Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.42, ATR14 : 3.57, CCI20 : -36.51, Chaikin Money Flow : 0.06, MACD : -1.62, Money Flow Index : 54.84, ROC : -0.70, RSI : 47.41, STOCH (14,3) : 67.14, STOCH RSI : 1.00, UO : 63.77, Williams %R : -32.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of DexCom Inc. in the last 12-months were: Barbara E. Kahn (Sold 2 766 shares of value $1 219 757 ), Barry J. Regan (Sold 2 212 shares of value $1 106 000 ), Chad Patterson (Sold 3 973 shares of value $1 701 249 ), Jereme M. Sylvain (Sold 3 000 shares of value $451 230 ), Kevin R. Sayer (Sold 55 607 shares of value $8 974 833 ), Matthew Vincent Dolan (Sold 4 377 shares of value $1 857 125 ), Paul R. Flynn (Sold 8 988 shares of value $1 110 018 ), Shelly Ramasamy Selvaraj (Sold 2 366 shares of value $949 405 ), Steven R. Pacelli (Sold 5 574 shares of value $1 051 855 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (80.00 %)
13 (81.25 %)
12 (80.00 %)
Moderate Buy
1 (6.67 %)
1 (6.25 %)
1 (6.67 %)
Hold
2 (13.33 %)
2 (12.50 %)
2 (13.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.31
Strong Buy
1.33

DexCom Inc.

DexCom Inc designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

CEO: Kevin R. Sayer

Telephone: +1 858 200-0200

Address: 6340 Sequence Drive, San Diego 92121, CA, US

Number of employees: 7 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

75%25%

Bearish Bullish

58%42%

Bearish Bullish

62%38%

Bearish Bullish

60%40%

TipRanks News for DXCM

Fri, 28 Oct 2022 16:32 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Dexcom (DXCM), Gilead Sciences (GILD) and Laboratory (LH)

- TipRanks. All rights reserved.

Fri, 28 Oct 2022 01:55 GMT Dexcom (DXCM) Receives a Buy from BTIG

- TipRanks. All rights reserved.

Fri, 07 Oct 2022 16:35 GMT Dexcom (DXCM) Gets a Buy from Stifel Nicolaus

- TipRanks. All rights reserved.

News

Stocktwits